PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.695 AUD 0.59% Market Closed
Market Cap: 988.6m AUD

PYC's latest stock split occurred on Feb 19, 2025

The company executed a 918-for-913 stock split, meaning that for every 913 shares held, investors received 918 new shares.

Before the split, PYC traded at 1.285 per share. Afterward, the share price was about 1.3.

The adjusted shares began trading on Feb 19, 2025. This was PYC's 8th stock split, following the previous one in Nov 15, 2024.

Last Splits:
Feb 19, 2025
918-for-913
Nov 15, 2024
1-for-10
Mar 18, 2024
85-for-84
Oct 22, 2020
407-for-404
Nov 4, 2019
372-for-365
Pre-Split Price
1.278 1.285
Post-Split Price
1.3
Before
After
Last Splits:
Feb 19, 2025
918-for-913
Nov 15, 2024
1-for-10
Mar 18, 2024
85-for-84
Oct 22, 2020
407-for-404
Nov 4, 2019
372-for-365

PYC Therapeutics Ltd
Stock Splits History

PYC Stock Splits Timeline
Feb 19, 2025
Feb 19, 2025
Split 918-for-913
x1.0054764512596
Pre-Split Price
1.278 1.285
Post-Split Price
1.3
Before
After
Nov 15, 2024
Nov 15, 2024
Split 1-for-10
/0.1
Pre-Split Price
1.8896 0.19
Post-Split Price
1.8399
Before
After
Mar 18, 2024
Mar 18, 2024
Split 85-for-84
x1.0119047619048
Pre-Split Price
0.8354 0.085
Post-Split Price
0.7956
Before
After
Oct 22, 2020
Oct 22, 2020
Split 407-for-404
x1.0074257425743
Pre-Split Price
1.8049 0.185
Post-Split Price
1.72
Before
After
Nov 4, 2019
Nov 4, 2019
Split 372-for-365
x1.0191780821918
Pre-Split Price
0.5935 0.062
Post-Split Price
0.5463
Before
After
Jul 7, 2015
Jul 7, 2015
Split 6-for-5
x1.2
Pre-Split Price
0.1197 0.015
Post-Split Price
0.134
Before
After
Dec 5, 2013
Dec 5, 2013
Split 85-for-81
x1.0493827160494
Pre-Split Price
0.1292 0.017
Post-Split Price
0.1356
Before
After
Sep 2, 2010
Sep 2, 2010
Split 81-for-80
x1.0125
Pre-Split Price
0.4054 0.054
Post-Split Price
0.4561
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.143 0.143 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.4 8.4 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 7, 2026
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
1-for-10
/10
0.35 0.35 EUR N/A
Load More

PYC Therapeutics Ltd
Glance View

Market Cap
994m AUD
Industry
Biotechnology

PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.

PYC Intrinsic Value
5.408 AUD
Undervaluation 69%
Intrinsic Value
Price
Back to Top